Support for HCM
Committed to people and their families living with Hypertrophic Cardiomyopathy
What is HCM?
HCM is the most prevalent of the inherited cardiomyopathies. It is a lifelong, often progressive condition that is frequently underdiagnosed. People with HCM may have a higher risk of heart failure, stroke, and atrial fibrillation. Commonly experienced symptoms include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood. This is known as “diastolic dysfunction.”
If you or a loved one have been diagnosed with cardiovascular disease and are experiencing any of the symptoms described above, talk to your doctor about genetic testing for HCM.
Medicines are available for HCM, but people taking may experience limited efficacy, undesirable safety concerns, inconvenient dosing, side effects, and the need for frequent monitoring. While progress has been made for the HCM community, new therapeutic approaches are needed.
Resources
Genetic Cardiomyopathy Awareness Consortium
Raises awareness about the need for genetic testing for cardiomyopathy patients and their family members.
Hypertrophic Cardiomyopathy Association (HCMA)
Provides support, advocacy, and education to patients, families, the medical community, and the public about hypertrophic cardiomyopathy while supporting research and fostering the development of treatments.
Mended Hearts
Inspires hope and improves the quality of life of cardiovascular disease patients and their families through ongoing peer-to-peer support, education, and advocacy.
Mended Hearts Europe
Fosters hope and enhances the lives of cardiovascular disease patients of all ages, their families, and caregivers across Europe. Through ongoing peer-to-peer support, patient education, and advocacy, their mission is to build a community characterized by resilience, care, and collective strength in overcoming challenges.
HCM Patient Foundation
Unites and supports individuals with HCM and their families across Europe.
Women Heart
Improves the lives of women with or at risk for heart disease while fighting for equity in heart health.
HeartCharged
Ends preventable deaths from sudden cardiac arrest and undiagnosed heart conditions and provides patient-to-patient support.
How do others live with HCM?
Meet Lindsay.
Patient Advocate. Author. Volunteer.
Living with HCM.
WHAT IS EDG-7500?
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, intended to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with symptomatic obstructive and nonobstructive HCM. EDG-7500 is currently in clinical trials in individuals with HCM.
EDG-7500 is an investigational therapy that has not been approved for use in hypertrophic cardiomyopathy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.
